Drug Trial Radar · NCT03341078
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
May 1, 2019
Primary completion
Oct 15, 2025
Study completion Oct 15, 2025
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Portland VA Medical Center; Oregon Health and Science University
- First posted
- Nov 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.
Conditions
- Methamphetamine-dependence
Interventions
IbudilastDrug
Ibudilast capsules will be orally ingested twice daily for 6 weeks.
Placebo Oral TabletDrug
Placebo capsules will be orally ingested twice daily for 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of ibudilast on brain function as assessed by magnetic resonance imaging (MRI)Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
VA Portland Health Care System, Portland, OR
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.